`
`Page 1
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
`
` __________
`
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
` __________
`
` PAR PHARMACEUTICAL, INC.,
` Petitioner,
`
` v.
`
` HORIZON THERAPEUTICS, LLC,
` Patent Owner.
`
` __________
`
` Case IPR2017-01767 (Patent 9,254,278)
` Case IPR2017-01768 (Patent 9,095,559)
` Case IPR2017-01769 (Patent 9,326,966)
`
` __________
`
` Deposition of
`
` GREGORY M. ENNS, M.B., Ch.B.
`
` Wednesday, July 18, 2018
`
`REPORTED BY: JOHN WISSENBACH, RDR, CRR, CRC
`
` CSR 6862
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 1 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 2
`
` INDEX OF EXAMINATIONS
`
` Page
`
`WITNESS:
`
`GREGORY M. ENNS, M.B., Ch.B.
`
` Examination by Mr. Silverstein 4
`
` Examination by Mr. Green 284
`
` ****
`
` E X H I B I T S
`
`No. Description Page
`
`Exhibit 1026 Inborn Metabolic Diseases, Diagnosis 4
` and Treatment, 3rd, Revised Edition,
` J. Fernandes, et al.,
` Springer-Verlag; Chapter 17,
` Disorders of the Urea Cycle, J.V.
` Leonard (title pages and pages
` 215-222)
`
` ****
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`1
`
`2 3
`
`4
`
`5
`
`6
`
`7
`
`8 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 2 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 3
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` BE IT REMEMBERED that, pursuant to the laws
`
`governing the taking and use of depositions, on
`
`Wednesday, July 18, 2018, commencing at 8:57 a.m.
`
`thereof, at the offices of Regus, 228 Hamilton Avenue,
`
`3rd Floor, Palo Alto, California, before me, JOHN
`
`WISSENBACH, a Certified Shorthand Reporter, personally
`
`appeared GREGORY M. ENNS, M.B., Ch.B., called as a
`
`witness by the Petitioner, who, being by me first duly
`
`sworn, was thereupon examined as a witness in said
`
`action.
`
` APPEARANCES OF COUNSEL
`
`For the Petitioner:
`
` AXINN, VELTROP & HARKRIDER LLP
` BY: DAVID H. SILVERSTEIN, Attorney at Law
` 114 West 47th Street
` New York, New York 10036
` (212) 261-5651 dsilverstein@axinn.com
`
` AXINN, VELTROP & HARKRIDER LLP
` BY: AZIZ BURGY, Attorney at Law
` 950 F Street, NW
` Washington, DC 20004
` (202) 721-5417 aburgy@axinn.com
`
`For the Patent Owner:
`
` GREEN, GRIFFITH & BORG-BREEN LLP
` BY: ROBERT F. GREEN, Attorney at Law
` ANN K. KOTZE, Attorney at Law
` 676 North Michigan Avenue, Suite 3900
` Chicago, Illinois 60611
` (312) 883-8080 rgreen@greengriffith.com
` (312) 883-8015 akotze@greengriffith.com
`
` ---o0o---
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 3 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 4
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` (Deposition Exhibit 1026 was marked for
`
`identification.)
`
` EXAMINATION BY MR. SILVERSTEIN
`
` Q. Good morning, Dr. Enns.
`
` A. Good morning.
`
` Q. My name is David Silverstein. I'll be taking
`
`your deposition today. Do you mind stating your full
`
`name and address for the record.
`
` A. Gregory Mark Enns. Shall I state my home or my
`
`work address?
`
` Q. Both.
`
` A. Okay. My home address is 907 Whitehall Lane,
`
`Redwood City, California 94601, and my work address is
`
`300 Pasteur Drive, Stanford, California 94305.
`
` Q. I think I've -- I've seen a couple of them, so
`
`I know you've been deposed a number of times, and you've
`
`testified a number of times; is that correct?
`
` A. Yes.
`
` Q. How many times have you been deposed?
`
` A. Approximately 30 to 35 times.
`
` Q. Okay. And how many of those were patent cases?
`
` A. The patent cases are a handful of times. I
`
`don't recall off the top of my head. It would be five
`
`or so, I think; maybe more. It's all a bit of a blur.
`
` Q. Have you testified at trial before?
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 4 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 5
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` A. Yes.
`
` Q. How many times?
`
` A. I've testified once for plaintiffs in a medical
`
`malpractice case by a video deposition for a trial. I
`
`was a defense expert in another medical malpractice
`
`case. And recently -- this wasn't a trial; it was an
`
`arbitration, so I'm not sure if that counts. But I
`
`testified in an arbitration recently.
`
` Q. Testified in any patent cases?
`
` A. No.
`
` Q. In your role as expert witnesses in patent
`
`cases, has it always been on the side of the brand?
`
` A. Yes.
`
` Q. Okay. Have you ever been sued before?
`
` A. Yes.
`
` Q. What was the nature of those matters?
`
` A. It was a single case, several years back now,
`
`related to a genetic test that I had performed in a
`
`patient I had seen once, ten years before getting notice
`
`of being sued. The case related to a laboratory result
`
`being report -- reported as negative, and then ten years
`
`later the laboratory redid the test and found out that
`
`they had made a mistake.
`
` Q. So was that a medical malpractice case?
`
` A. It was.
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 5 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 6
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` Q. And you were a defendant in the case?
`
` A. I was, yes.
`
` And just for the record, I was dismissed from
`
`it, and it was all gone away without a settlement or
`
`anything else.
`
` Q. Okay. Just to review briefly the ground rules
`
`for the deposition, if I ask a question and you answer,
`
`I'm going to assume that you understood the question
`
`unless you ask me to clarify or you ask another
`
`question. Do you understand that?
`
` A. Yes.
`
` Q. Okay. For today's deposition, unless I specify
`
`otherwise, I want you to assume that the time frame of
`
`my questions is as of 2011. Do you understand that?
`
` A. Yes.
`
` Q. As you know, for the court reporter, verbal
`
`answers are -- make the record clearer, so "yes"/"no" is
`
`better than nodding. If you'd like to take a break, I'm
`
`happy to indulge you, but just as long as there's not a
`
`question pending.
`
` What did you do to prepare for today's
`
`deposition?
`
` A. I read my declaration, and I met with counsel
`
`yesterday to go over my declaration, and I reviewed some
`
`of the exhibits related to this matter, as well as
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 6 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 7
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`reading the declaration testimony of Dr. Sondheimer. I
`
`also reviewed the patents in question.
`
` Q. Did you review any other documents?
`
` A. I think that's the totality of what I reviewed.
`
` Q. Okay. Did you review the final written
`
`decision in the IPR that Lupin filed on the '559 patent?
`
` A. No.
`
` Q. Have you ever reviewed it?
`
` A. No.
`
` Q. Did you review the final written decision on
`
`the '215 patent?
`
` A. No.
`
` Q. Okay. You understand by "'215 patent," I mean
`
`it's the parent patent of the '559 patent?
`
` A. Yes.
`
` Q. Okay. And just a little point of clarity. So
`
`you said you reviewed your declaration. So this is a
`
`consolidated deposition for all three, the '559, '278,
`
`to '966 patent IPRs. Do you understand that?
`
` A. Yes.
`
` Q. And I assume you reviewed all three
`
`declarations, or just one of them?
`
` A. Well, I reviewed the '559 primarily, and I
`
`looked through the other declarations in brief. But
`
`they're all dealing with similar material.
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 7 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 8
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` Q. And for ease of today's proceeding, I'll
`
`provide you all three, but we'll focus the discussion on
`
`the '559. If there's any substantive differences in the
`
`other two declarations when I ask a question and you're
`
`answering, please -- please point that out if you feel
`
`the need.
`
` A. Okay.
`
` Q. Did you take any notes during your preparation
`
`yesterday with counsel?
`
` A. I took some notes, yes.
`
` Q. Did you -- did you bring them with you?
`
` A. I have some of the notes with me, yes. I'm not
`
`sure if I brought them all. I haven't reviewed them
`
`since yesterday.
`
` Q. Okay.
`
` A. But I've got my briefcase that I took with me
`
`to the meeting.
`
` Q. Did you bring any other documents with you
`
`today?
`
` A. I did. I've got copies of my declarations in
`
`hard copy, and I've got a file that I've used in the
`
`past for past matters related to Horizon. I also have
`
`my computer, and that has the exhibits and other
`
`materials on electronic files, as well.
`
` Q. Okay. Did you conduct the search -- searches
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 8 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 9
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`for the prior art that you rely on in the '559, '966,
`
`and '278 declarations?
`
` A. It was a combination, I would say. I, of
`
`course, know the literature well, and I conducted
`
`searches related to that, but I was also provided
`
`materials that had to deal with the prior art.
`
` Q. The prior art you do rely on in your
`
`declarations, do you believe they're reliable and
`
`accurate?
`
` A. Well, as far as "reliable and accurate" goes,
`
`these are published materials that are in the record. I
`
`would have to review each document to determine the
`
`extent of the reliability per se. But they're
`
`reasonable documents, that have been published in
`
`peer-reviewed journals, for the most part, but there are
`
`other statements, such as packet inserts and other
`
`documents, in there as well, so I would have to -- as a
`
`blanket, to say that perhaps one by one I would have to
`
`look at it to discuss the precise reliability.
`
` Q. Uh-huh. But to your knowledge, are there any
`
`prior art references you rely on in these matters that
`
`are not reliable?
`
` A. Well, reliability, again, is a matter of
`
`exactly what -- what is stated in each exhibit, for
`
`example. A book is typically not peer reviewed, whereas
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 9 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 10
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`a medical article appearing in a journal would have some
`
`peer review, typically, unless it is a review article.
`
`Sometimes abstracts have been listed as part of
`
`exhibits, and they don't, of course, carry the weight as
`
`a -- of -- a peer-reviewed article would, et cetera. So
`
`in general these are parts of the prior art that have
`
`been published, and depending upon the publication
`
`process and the peer review process and the actual, for
`
`example, number of patients reviewed, a case report
`
`versus a -- a large study involving lots of patients,
`
`the reliability is going to vary from subject matter to
`
`subject matter.
`
` Q. Is it safe to say, though, if you relied on a
`
`prior art reference, that in your opinion that reference
`
`would be relevant to a POSA in the context of these
`
`IPRs?
`
` A. I think overall that would be a safe summary.
`
` Q. What is your current position?
`
` A. I'm a professor of pediatrics in the Department
`
`of Pediatrics in the Division of Medical Genetics at
`
`Stanford University.
`
` Q. And do you treat UCD patients?
`
` A. Yes.
`
` Q. Approximately how many currently?
`
` A. Currently approximately 40, I think.
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 10 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 11
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` Q. And what -- what ages?
`
` A. Ages range from infants to adults. The oldest
`
`adult that I was treating passed away. He was in his
`
`seventies or eighties. So generally the adults that I'm
`
`currently following are in their fifties, and there's a
`
`collection of maybe a handful of infants that I
`
`currently follow as well, so in between. The majority
`
`would be in the childhood range.
`
` Q. The patient that passed away, did they acquire
`
`UCD congenitally?
`
` A. Yes. This was a congenital abnormality. It
`
`was genetic defect.
`
` Q. Around 2011, how many UCD patients were you
`
`treating?
`
` A. 2011, it was probably relatively similar. It
`
`comes and goes a little bit with referrals and patients
`
`coming in and out of town. One of the most common
`
`things that happens in our practice, because we're a
`
`known center for this, is patients come in from around
`
`the world for liver transplantation, for example. I
`
`might follow that patient for a period of time, and then
`
`they go back to their home base. But I think it's been
`
`fairly steady over the last -- last eight or so years to
`
`be following continuously around 40 patients.
`
` Q. What is your understanding of treatment of
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 11 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 12
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`chronic UCDs?
`
` A. It's a pretty broad question.
`
` Q. Well, let me ask it different: chronic versus
`
`acute?
`
` A. Okay.
`
` Q. Would you categorize the types of UCD treatment
`
`in those -- with those two labels, or would you use
`
`something else?
`
` A. Yeah, again, it really depends, because a
`
`patient who is on chronic treatment might have a
`
`biochemical crisis associated with hyperammonemia that
`
`would go into an acute phase, for example. A new
`
`patient who has not been treated at all might have an
`
`acute metabolic crisis, requiring significant rescue
`
`therapy, which would then be transferred into more
`
`chronic management.
`
` So it's a little bit of a continuum in some
`
`ways, and in others -- the general feeling, I would say,
`
`is an acute treatment is typically associated with a --
`
`a metabolic crisis or a hyperammonemic state that needs
`
`some acute intervention. However, chronic management
`
`also involves some degree of acute intervention, too, as
`
`far as adjusting medication dosages, that might not
`
`necessarily require admission to hospital, or changing
`
`the diet, that might not necessarily require admission.
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 12 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`So it's, I think, a bit of a continuum.
`
` Q. In your care of the about 40 UCD patients
`
`currently, do you care for the -- do you chronic -- are
`
`you involved in chronic management of the UCD or acute
`
`treatment?
`
` A. Both. As far as the acute therapy would go, I
`
`also have a colleague, who has started within the last
`
`couple of years, to my great delight, where I cannot
`
`necessarily be involved in the acute management unless
`
`I'm specifically on call or if there's a specific
`
`question that arises that my colleague might have. So
`
`I'm on call as what we call a biochemical backup at
`
`least six months of the year, and we share that call
`
`with my colleague, who is also a biochemical geneticist.
`
` Q. Uh-huh. So other than, I believe you
`
`mentioned, adjusting the dose and changing the diet in
`
`the context of chronic management, what other courses of
`
`action might you take in treating those patients for
`
`chronic UCD?
`
` A. Chronic therapy involves a comprehensive
`
`evaluation of the patient and family. So a patient
`
`would be seen in the context of our biochemical genetics
`
`clinic, and that includes evaluation medically by -- by
`
`me or my colleague. It includes a dietician evaluation
`
`of nutritional status and current dietary practices,
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 13 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 14
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`also a nurse evaluation if -- these children typically
`
`or often are on G-tube feeds or other things.
`
` (Discussion off the record.)
`
` THE WITNESS: G-tube, gastrostomy tube, feeds.
`
` So a nurse is also there and available, as is
`
`a -- as is a social worker, who -- who looks at the
`
`overall family dynamics and other things.
`
` So from that evaluation, we make an assessment
`
`of what the needs are of that individual patient.
`
`Individual patients will have a range of biochemical
`
`abnormalities associated with their underlying enzyme
`
`defect. A urea cycle patient has a variety of different
`
`potential levels of severity, for example. So assessing
`
`the severity of the patient's clinical status is part of
`
`what we do.
`
` We provide the patients all with an emergency
`
`management protocol, as well as an emergency letter.
`
`The emergency letter is typically used for, as we were
`
`discussing before, a transition to a more acute phase.
`
`If the child is acutely unwell, there would be a need to
`
`be evaluated promptly to -- to initiate other therapy,
`
`potentially, and we don't want these patients lounging
`
`around in the emergency department. We need them to be
`
`looked upon quickly.
`
` So part of that is, I think, general education,
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 14 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 15
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`et cetera; also, evaluating the state of hospital stays
`
`and neurological status and providing guidance on a
`
`variety of different treatments. You mentioned diet and
`
`medication therapy, which are part of it, of course.
`
`Dietary involvement is also using special nutritional
`
`supplements that are not just a low-protein diet, but
`
`essential amino acid supplements that are used in
`
`treating these disorders. And the other thing, of
`
`course, is providing guidance on such things as liver
`
`transplantation and how we follow these patients
`
`before/after transplantation.
`
` So it's a global interaction, with a lot of
`
`inputs and a lot of different people working on the
`
`management of these patients.
`
`BY MR. SILVERSTEIN:
`
` Q. So as far as your involvement, though,
`
`everything you listed is what you were involved with
`
`personally, or -- I guess I'm just --
`
` A. I --
`
` Q. The line's a little blurry of --
`
` A. Right.
`
` Q. -- consulting with -- with others versus
`
`what --
`
` A. No, I can -- I can see.
`
` So I would be the -- the sort of person where
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 15 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 16
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`the buck stops. So I -- I would be the one who would be
`
`guiding the overall care and evaluation of the patient.
`
`Our dietician would provide me with data related to the
`
`amount of protein intake, for example, a child is
`
`experiencing. We would look at laboratory values, such
`
`as amino acids and other values, in order to determine
`
`whether protein intake, for example, is adequate for
`
`growth. We would be monitoring growth chart, and things
`
`like that. So I would interact with that individual,
`
`and together we would come up with a reasonable plan,
`
`that would have to be okayed in its final form by me.
`
`However, there are a lot of different inputs. And
`
`that's why you need a team approach here.
`
` Q. It sounds like, if I'm understanding you
`
`correctly, as a physician chronically managing a UCD
`
`patient, you're involved in treatment, diagnosis, and
`
`counseling. Is that right?
`
` A. I think that's fair. We also -- and thank you
`
`for reminding me. We also have genetic counselors, who
`
`are seeing patients, as well as our residents in
`
`training and fellows in training, who will also see
`
`these patients. So part of what we're doing is
`
`education. And there are genetic counseling aspects to
`
`this as well. However, for the very basic going over
`
`inheritance patterns and how things are transmitted down
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 16 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 17
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`the family line, et cetera, we will often resort to
`
`using our genetic counselors, because they have
`
`tremendous experience in talking to families about this,
`
`et cetera. But --
`
` Q. Right.
`
` A. You know, that's also part of what I do, yes.
`
` Q. As part of chronic management, do you -- let me
`
`back up. So you had mentioned a plan for -- or you say
`
`a guidance -- strike that.
`
` A moment ago, you mentioned as part of the
`
`chronic management you'd offer guidance of liver
`
`transplantation. So just to be clear, liver
`
`transplantation, is that part of chronic management?
`
` A. Well, it's part of seeing a patient who's being
`
`managed chronically. And post transplantation we will
`
`also follow these children to see how they're doing, but
`
`their acute need is much less, because once you've
`
`transplanted a liver, the -- there's no longer any
`
`further danger of having elevated ammonia, as long as
`
`that liver is functioning well.
`
` So it is a part of chronic management seeing
`
`how the family is doing post transplant, following
`
`alongside our liver transplant team, but that's a much
`
`easier visit for us, because we're no longer prescribing
`
`medications or offering dietary management, because the
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 17 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 18
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`diet is liberalized once a liver transplantation is in
`
`place. However, we have a tendency to provide amino
`
`acid supplements, because liver transplantation will not
`
`completely correct certain amino acid deficits that are
`
`present because of the urea cycle defect in some cases.
`
` Q. Got it. And you'd also mentioned as part of
`
`the chronic treatment or management there's the
`
`emergency management protocol and letter. Is -- are you
`
`saying that emergency management is part of chronic
`
`management?
`
` A. I'm saying it's -- education is part of chronic
`
`management. So the -- it's important, when seeing our
`
`patients, to make sure that the family or the patient
`
`understands the need to be seen acutely and any sort of
`
`an illness that can cause catabolism especially, because
`
`those are illnesses that can result in a high ammonia
`
`level.
`
` So we go over with them, typically, an
`
`emergency protocol in basic terms and make sure that
`
`they understand if -- if it's an adult and you're
`
`feeling woozy or lethargic or you're vomiting and not
`
`taking in normal food, that you make sure you be seen
`
`quickly. And we also make sure that that individual or,
`
`in the case of a child, the family will have an
`
`emergency letter that explains the underlying diagnosis,
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 18 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 19
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`that they can use as almost an insurance policy when
`
`they're going to their own physician or to the emergency
`
`department, so that they're taken into consideration
`
`rapidly and seriously.
`
` Q. If they become acute?
`
` A. If they become acute.
`
` (Discussion off the record.)
`
` MR. SILVERSTEIN: "If they become acute."
`
` THE WITNESS: Correct, if they come -- if they
`
`become acute. But it's -- also part of chronic
`
`management is this educational process, I would say,
`
`making sure patients understand the needs to be seen
`
`rapidly and know that we're always available for them if
`
`need be.
`
`BY MR. SILVERSTEIN:
`
` Q. Okay. The genetic counselors you mentioned,
`
`are they practicing medical doctors?
`
` A. No. No, they typically have master's of
`
`science in genetic counseling, and they -- they're
`
`licensed as certified genetic counselors.
`
` Q. What about the dieticians? Are they medical
`
`doctors?
`
` A. No.
`
` Q. Okay.
`
` A. But they're -- again, the dieticians would be
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 19 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 20
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`registered dieticians.
`
` Q. Is blood dialysis part of chronic management?
`
` A. No, typically that would be acute-phase
`
`management. Hemodialysis would -- would be used in the
`
`acute treatment of hyperammonemia, in particular in
`
`cases where there's a very high level of ammonia in a
`
`patient who is lethargic, going into a coma, or
`
`comatose.
`
` Q. And what do you mean by "very high level" of
`
`ammonia?
`
` A. That's a good -- good question.
`
` For dialysis, typically we're invoking
`
`hemodialysis or hemodiafiltration when ammonia levels
`
`are above approximately 600 micromolar. If they're
`
`between 200 to 600 micromolar, oftentimes we're
`
`successful in lowering the ammonia level with nitrogen
`
`scavenging medications given IV plus providing high
`
`caloric support given IV as well.
`
` However, the way it works, and the way it
`
`should work, is if a patient is coming in with rising
`
`ammonia and altered mental status, especially over
`
`200 micromolar, the IVs are being placed, and we're
`
`monitoring these patients for their hyperammonemia
`
`situation and their clinic status, and we might be able
`
`to get a response just with what I would say medical
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 20 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 21
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`management without dialysis.
`
` Q. Okay.
`
` A. However, dialysis catheters are often being
`
`placed and the nephrology team is being contacted
`
`simultaneously to be in place just in case this medical
`
`management doesn't work as we would hope it would.
`
` Q. Okay.
`
` A. Sometimes we have a patient who is what we
`
`would say a frequent flyer, who comes in relatively
`
`frequently, and we know what his or her response is
`
`likely to be, and likely they will respond to fluid
`
`resuscitation with intravenous medications, for example,
`
`and we would not need dialysis in that situation or the
`
`emergent call to put in a dialysis catheter. We'd
`
`typically just alert the team to know that they're
`
`coming in, that a patient is coming in; and alerting the
`
`team, I mean the nephrology team, to be aware.
`
` So it really depends upon our experience with
`
`the patient, as well. But in general, hemodialysis or
`
`any sort of dialysis is an acute event.
`
` Q. So what about -- you mentioned IV medication.
`
`So those are part of acute treatment. Are they part of
`
`chronic management?
`
` A. Intravenous medications are typically not part
`
`of chronic management, but they can be in -- in some
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 21 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 22
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`situations. We have had the unfortunate experience of
`
`having patients be very difficult to treat as far as
`
`maintaining a -- ammonia levels in an acceptable range.
`
`And oftentimes, I would say -- "oftentimes." We've had
`
`a handful of these patients where they've been sent to
`
`our facility because they've had ammonia levels that
`
`have been unable to be controlled with the typical
`
`management of diet plus enteral, and while waiting for
`
`liver transplantation or while being prepared for liver
`
`transplantation, we would have to have a handful of
`
`patients on IV nitrogen scavengers for a variety of
`
`reasons that have lasted for weeks. So in a sense,
`
`that's not really acute management; it's -- it's, maybe,
`
`subacute on chronic management for period -- periods
`
`that can lengthen into several weeks. But those types
`
`of situations, fortunately, are relatively rare.
`
` Q. Okay. So you had mentioned for these patients
`
`it's difficult to maintain the ammonia level in, as you
`
`put it, an acceptable range. But what is an acceptable
`
`range for treatment of UCD patients?
`
` A. Right. It really depends upon the patient that
`
`we're talking about, because patients are going to have
`
`different enzymatic activities, for example, and
`
`different typical severity of disease. However,
`
`acceptable range today, that most people shoot for, is
`
`GregoryEdwards, LLC | Worldwide Court Reporting
`GregoryEdwards.com | 866-4Team GE
`
`Par Pharmaceutical, Inc. Ex. 1027
`Par v. Horizon, IPR2017-01767
`Page 22 of 294
`
`
`
`Gregory M. Enns, M.B., Ch.B. - July 18, 2018
`
`Page 23
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`often between around 60 to 80 micromolar.
`
` Q. Is that -- is that the same as saying that the
`
`upper limit of normal is 60 to 80 for these patients?
`
` A. No. Upper limit of normal is a laboratory
`
`construct. It's something that laboratories provide
`
`related to normative ranges of various laboratory
`
`results. An acceptable range would be related to what
`
`the physician and team and the patient accepts as being
`
`a reasonable treatment goal for a patient, related to
`
`ammonia in this case, but t